CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Tecentriq & Avastin for Hepatocellular Carcinoma - Details

Project Number pCODR 10217
Brand Name Tecentriq & Avastin
Generic Name Atezolizumab & Bevacizumab
Tumour Type Gastrointestinal
Indication Hepatocellular Carcinoma (HCC)
Funding Request TECENTRIQ (atezolizumab), in combination with AVASTIN (bevacizumab), for the treatment of patients with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy. Maintenance TECENTRIQ should be continued until loss of clinical benefit or unacceptable toxicity. Maintenance AVASTIN should be continued until disease progression or unacceptable toxicity.
Review Status Under Review
Pre Noc Submission No
NOC Date
Manufacturer Hoffmann-La Roche Limited
Sponsor Hoffmann-La Roche Limited
Submission Date May 21, 2020
Submission Deemed Complete June 4, 2020
Submission Type New Indication
Prioritization Requested
Stakeholder Input Deadline ‡ June 4, 2020
Check-point meeting (target date) August 6, 2020
pERC Meeting (target date)
Initial Recommendation Issued (target date)
Feedback Deadline (target date) ‡
pERC Reconsideration Meeting (target date)
Final Recommendation Issued (target date)
Notification to Implement Issued

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.